| Τίτλος – Title | Κλινική φαρμακολογία των Αντιψυχωσικών και Αγχολυτικών φαρμάκων
Clinical Pharmacology of Antipsychotic and Antianxiety Drugs |
|
| Συγγραφέας – Author | Χαράλαμπος Τρ. Πλέσσας
Charalambos T. Plessas |
|
| Παραπομπή – Citation | Πλέσσας, X.: Κλινική φαρμακολογία των Αντιψυχωσικών και Αγχολυτικών φαρμάκων, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 2(1): 28-41 (1984)
Plessas, C.: Clinical Pharmacology of Antipsychotic and Antianxiety Drugs, Epitheorese Klin. Farmakol. Farmakokinet. 2(1): 28-41 (1984) |
|
| Ημερομηνία Δημοσιευσης – Publication Date | Απρίλιος 1984 – April 1984 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language |
Ελληνικά – Greek | |
| Παραγγελία – Αγορά – Order – Buy |
Ηλεκτρονική Μορφή: pdf (15 €) – Digital Type: pdf (15 €) pharmakonpress[at]pharmakonpress[.]gr |
|
| Λέξεις κλειδιά – Keywords | Ψυχιατρική, φάρμακα, άγχος, σχιζοφρένεια
Psychiatrics, drugs, anxiety, schizophrenia |
|
| Λοιποί Όροι – Other Terms | Άρθρο Article |
|
| Περίληψη – Summary | Antipsychotic drugs ameliorate the course of schizophrenia by blocking dopaminergic receptors in the mesolimbic area and evoke extrapyramidal syndromes and cause unwanted pituitary-endocrine effects by blocking the same receptors in both the globus pallibus and corpus striatum and in the hypothalamus. Phenothiazines, the commonly used antipsychotic drugs, are characterized by a partial absorption in the gastrointestinal tract, an increased distribution in all tissues and organs, a high degree of protein binding and undergo N-demethylation, hydroxylation, sulfoxidation, O-methylation, side chain dealkylation and N-oxydation. Their metabolites have been found in human urine and feces. Haloperidol, the prototype of butyrophenones, is rapidly absorbed with a systemic availability of 60-70%, is about 92% protein bound and has a large distribution volume. The metabolism of haloperidol involves a primary step of N-dealkylation that results in a series of non-active metabolites. Many of the a n t i anxiety drugs, including the benzodiazepines, possess varying degree of the pharmacological actions of sedative-hypnotics and others affect the peripheral autonomic nervous system. Benzodiazepines affect only specific brain sites-spinal centers, the limbic system and the reticular activating system (RAS: is probably not the primary site of action). The muscle relaxant component of their action is at the spinal level. Benzodiazepines are rapidly absorbed after oral administration, but slowly and erratically after i.m. administration. They are found distributed in all body tissues and especially in the adipose tissue and brain and bound highly to plasma proteins. Benzodiazepines form active metabolites, some of which (N-desmethyldiazepam, N-desmethyl-chlordiazepoxide) are more slowly eliminated than the parent drugs. Some members of benzodiazepines (p.ex. clorazepate) are prodrugs of their active metabolites. The metabolites are excreted mainly in urine as glucuronide conjugates. | |
| Αναφορές – References | 1. Carlsson, A.: Antipsychotic drugs, neurotransmitters and schizophrenia Am. J. Psych. 135: 164 (1978)
2. Hollister, L.E.: Clinical Use of Psychotherapeutic Drugs. Thomas, Springfield, 1973 3. McGeer, P.L., McGeer, E.G.: Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch. Gen. Psychiatry 34: 1319 (1977) 4. Antelman, S.M., Caggiula, A.R.: Norepinephrine-dopamine interactions and behavior. Science 795: 646 (1977) 5. Gringauz, A.: Drugs: how they act and why. The C.V. Mosby Co., Saint Louis, 1978 6. Wise, C.D., Berger, B.B., Stein, L.: Benzodiazepines: Anxiety-reducing activity for reduction of Serotonin turn-over in the brain. Science 177: 180 (1972) 7. Greenblatt, D.J., Shader, R.I.: Benzodiazepines in Clinical Practice. Paven Press, New York, 1974 8. Fann, W.E., Davis, J.M., Janowsky, D.S., Sekerke, H.J., Schmidt, D.M.: Chloropromazine: Effects of antacids on its gastrointestinal absorption, J. C/in. Pharm. 13: 388 (1973) 9. Rivera-Calimlin, L., Castanneda, L., Lesagna, L.: Effects of mode of management on Plasma Chloropromazine in psychiatric patients. CUn. Pharmacol. Then 14:978 (1973) 10. Curry, S.H., Mould, G.P.: A microsomal oxidase System in rat intestinal mucosa. Br. J. Pharmacol. 54: 229p (1975) 11. Rivera-Calimlim, Kerzner, B., Karch, F.E.: Effect of lithium on plasma chioropromazine levels. Clin. Pharmacol. Ther. 23: 451 (1978) 12. Curry, S.H., Davis, J.M., Janowsky, D.S., Marshall, J.H.L. Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch. Gen. Psychiatry 22: 209 (1970) 13. Garattrni, S., Morselti, P.L.: Metabolism and pharmacokinetics of Psychotropic Drugs. In: Principles of Psychopharmacology, p. 169, Academic Press, New York, 1978 14. Forrest, I.S., Carr, C.J., Usdin, E., Eds: The Phenothiazines and Structurally Related Drugs. Raven Press, New York, 1974 15. Bickel, M.H.: Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components. J. Pharm. Pharmacol. 27: 733 (1976) 16. Williams, R.T., Parke, D.V.: The metabolic fate of Drugs. Ann. Rev. Pharmacol. 4: 85 (1964) 17. Turano, P., Turner, W.J., Manían, A.A.: Thinlayer chromatography of chlorpromazine metabolites. Attempt to identity each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics. J. Chromatogr, 75: 277 (1973) 18. Coccia, P.F., Westerfeld, W.W.: The metabolism of chlorpromazine by liver microsomal enzyme systems. J. Pharmacol. Exp. Ther. 157: 446 (1967) 19. Kaul, P.N., Conway, M.W., Ticku, M.K., Clark, M.L.: Chlorpromazine metabolism II: Determination of nonconjugated metabolites in blood of schizophrenic patients. J. Pharm. Sci. 61: 581 (1972) 20. Salzman, N.P., Moran, N.C., Brodie, B.B.: Identification and pharmacological properties of a major metabolite of chlorpromazine. Nature 176: 1122 (1955) 21. Prema, K., Gopinathan, K.P.: Distribution, induction and purification of a monooxygenase catalyzing sulphoxidation of drugs. Biochem. Pharmacol. 25: 1299 (1976) 22. Gorrod, J.W., Lazarus, C.R., Beckett, A.H.: Some aspects of the in vitro oxidation of 35S-chloropromazine. Adv. Biochem. Psychopharmacol. 9: 191 (1974) 23. Maickel, R.P., Fedynskys. N.M., Potter, W.Z., Manían, A. A.: Tissue localization of 7- and 8-hydroxychlorpromazines. Toxicol. Appl. Pharmacol. 28: 8 (1974) 24. Alfredsson, G., Wiesel, F.-A., Skett, P.: Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion. Psychopharmacology 53: 13 (1977) 25. Wiles, D.H., Kolakowska, T., McNeilly, A.S., Mandelbrote, B.M., Gelder, M.G.: Clinical significance of Plasma Chlorpromazine levels. I. Plasma levels of the drug, somme of its metabolites and prolactin during acute treatment. Psychol. Med. 6: 407 (1976) 26. Dingell, J.V., Sossi, N.: Studies on the glucuronidatton of 7-hydroxy chlorpromazine in vitro. Drug Metab. Dispos. 5: 397 (1977) 27. Fishman, V., Heaton, A., Goldenberg, H.: Metabolism of chlorpromazine. III. Isolation and identification of chiorpromazine-N-oxide. Proc. $oc. Exp. Biol. Med. 109: 548 (1962) 28. Beckett, A.H., Hewick, D.S.: The N-oxidation of chlorpromazine in vitro-the major metabolic route using rat liver microsomes, J. Pharm. Pharmacol 19: 134 (1967) 29. Loga, S., Curry, S., Lader, M.: Interactions of orphenadrine and phenobarbitone with chlorpromazine: Plasma concentrations and effects in man. Br. J. Clin. Pharmacol 2: 197 (1975) 30. Forrest, F.M., Forrest, I.S., Finkle, B.S.: Alcohol chlorpromazine interaction in psychiatric patients. Agressologie 13: 67 (1972) 31. Swett, C.: Drowsiness due to chlorpromazine in relation to cigarette smoking. Arch. Gen. Psychiatry 31: 211 (1974) 32. Curry, S.H.: Metabolism and Kinetics of chlorpromazine in relation to effect, in: Antipsychotic Drugs: Pharmacodynamics and pharmacokinetics (G. Sedvall, B. Uvnas, Y. Zottermann, eds), p.p. 343-352, Pergamon Press, New York, 1975 33. May, P.R.A., Putter, T. Van: Piasma levels of chlorpromazine in schizophrenia. Arch. Gen. Psychiatry 35: 1081 (1978) 34. Alfredsson, G., Wode-Helgodt, B., Sedvall, G.: A mass fragmelographic method for the determination of chlorpromazine and two of its active metabolites in human piasma and CSF. Psychopharmacology 48: 123 (1976) 35. Wode-Helgodt, B., Borg, S., Fyro, B., Sedvall, G.: Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiat. Scand. 58: 149 (1978) 36. Sakalis, G., Curry, S.H., Mould, G.P., Lader, M.H.: Psysiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin. Pharmacol. Thar. 13: 931 (1972) 37. Mantersson, E., Ross, B.E.: Serum levels of thioridazine in psychiatric patients and healthy volunteers. Eur. J. Clin. Pharmacol. 6: 181 (1973) 38. Muusze, R.G., Vanderheeren, F.A.: Piasma levels and half lives of thioridazine and some of its metabolites. II. Low dose in older psychiatric patients. Eur. J. Clin. Pharmacol. 11: 141 (1977) 39. Nyberg, G., Axelsson, R., Martensson, E.: Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur. J. Clin. Pharmacol. 14: 341 (1978) 40. Zingales, I.A.: Detection of chlorpromazine and thioridazine metabolites in human erythrocytes. J. Chromatogr. 44: 547 (1969) 41. Israili, Z.H., Dayton, P.G., Kiechel, J.R.: Novel routes of drug metabolism. A survey. Drug Metab. Dispos. 5: 411 (1977) 42. Forsman, A., Ohman, R.: Some aspects of the distribution and metabolism of haloperidol in man. In: Antipsychotic drugs: Pharmacodynamics and Pharmacokinetics (G. Sedvall, B. Unvas, Y. Zotterman, eds), p. 359, Pergamon Press, Oxford, 1975 43. Forsman, A., Ohman, R.: Studies on serum protein binding of haloperidol. Curr. Ther. Res. 21: 245 (1977) 44. Soudijh, W., Van Wijngaarden, I., Allewijn, F.: Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Part 1. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the wistar rat. Eur. J, Pharmacol. 1: 47 (1967) 45. Van den Eeckhout, E., Belpaire, F.M., Bogaert, M.G., De Moerloose, P.: Radioimmunoassay of bromperidol and haloperidol in human and canine plasma. Eur. J. Durg Metabol. Pharmacok. 5: 45 (1980) 46. Mandelli, M., Tognoni, G., Garattini, S.: Clinical Pharmacokinetics of diazepam. Clin. Pharmacok. 3: 72 (1978) 47. Gamble, J.A.S., Dundee, J.W., Assaft, R.A.E.: Plasmadiazepam levels after single dose oral and intramuscular administration. Anaesthesia 30: 164 (1975) 48. Hillestad, L., Hansen, T., Melsom, H., Drivines, A.: Diazepam metabolism in normal man. 1. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration. Clin. Pharmacol. Ther. 16: 479 (1974) 49. MacLeod, S.M., Giles, H.G., Bengert, B., Lin, F., Sellers, E.M.: The influence of age and sex on diazepam pharmacokinetics. Clin. Res. 25: 676A (1977) 50. DeSilva, J.A.F., Koechlin, B.A., Bader, G.: Blood level distribution patterns of diazepam and its major metabolite in man. J. Pharm. Sci. 55: 692 (1966) 51. Hillestad, L., Hansen, T., Melsom, H.: Diazepam metabolism in normal man. II. Serum concentrations and clinical effects after oral administration and cumulation. Clin. Pharmacol. Ther. 16: 485 (1974) 52. Kanto, J., lisalo, E., Lehtinen, V., Salminen, J.: The concentrations of diazepam and its metabolites in the plasma after an acute and chronic administration. Psychopharmacologia 36: 123 (1974) 53. Tognoni, G., Comeni, R., De Maio, D., Hberti, G.G., Franciosi, P., Scieghi, G.: Pharmacokinetics of N-deme thyldiazepam in patients suffering – from insomnia and treated with nortriptyline. Br. J. Clin, Pharmacol. 2: 227 (1975) 54. Greenblatt, D.J., Shader, B.I., Koch-Weser, J.: Pharmacokinetics in chimical medicine: oxazepam versus other benzodiazepines. Dis. Nerv. Syst. 36: 6 (1975) 55. Greenblatt, D.J., Shader, R.I., Weinberger, D.R., Allen, M.D., MacLaughlin, D.S.: Effect of cocktail on diazepam absorption. Psychopharmacology 57: 199 (1977) 56. Gottschalk, L.A., Biener, R., Dinovo, E.C.: Effect of oral and intramuscular routes of administration on serum chlordiazepoxide levels and the prediction of these levels from predrug fasting serum glucose concentrations. Res. Commun. Chem. Pat hoi. Pharmacol. 8: 697 (1974) 57. Greenblatt, D.J., Shader, R.I., MacLeod, S.M., Sellers, E.M.: Clinical pharmacokinetics of chlordiazepoxide. Clin. Pharmacok. 3: 381 (1978) 58. Schwartz, M.A., Postma, E.: Metabolite of demoxepam, a chlordiazepoxide metabolite in man. J. Pharm. Sci. 61: 1310 (1972) 59. Dixon, R., Brooks, M.A., Postma, E., Hackman, M.R., Spector, S., More, J.D., Schwartz, M.A.: N-desmethyldiazepam: A new metabolite of chlordiazepoxide in man. Clin. Pharmacol. Ther. 20: 450 (1976) 60. Greenblatt, D.J., Shader, R.I., Koch-Weser, J.: Clinical pharmacokinetics of chlordiazepoxide. In: Pharmacokinetics of Psychoactive Drugs, p. 127, Spectrum Publications, New York, 1976 |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition-Instrunctions to Authors
Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1984 – ANNUAL SUBSCRIPTION 1984 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language |
Ελληνικά – Greek |
| Παραγγελία – Αγορά – Order – Buy |
Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) Printed Type (70 € + shipping)pharmakonpress[at]pharmakonpress[.]gr |
|